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We have added nine extra residues to the C-terminal of human prolactin and analysed the effect 
of this mutation on the ability of the hormone to bind to its lactogenic receptor and to induce Nb2 
cell division. Both properties are markedly affected when compared to the natural 23-kDa human 
prolactin. Since no alteration of the global protein folding was detected either by circular dichroism 
or by infrared spectroscopy, the decrease in biological potency can be exclusively attributed to an 
effect of the nine additional residues on their near environment. From infrared analysis and second- 
ary structure prediction, the elongated tail is assumed to be involved in a B-sheet with a few residues 
initially belonging to the fourth helix. Moreover, from the X-ray structures of porcine and human 
growth hormones, two proteins homologous to prolactins, the nine extra residues are likely to fold 
within a concave pocket delimited by helices 1 and 4, and the second half of the loop connecting 
helices 1 and 2 (loop 1). Thereby, we suggest that the additional residues prevent some residues 
belonging to this pocket from interacting with the lactogenic receptor. This is in perfect agreement 
with our earlier proposal that the binding site of prolactin to the lactogenic receptor is homologous 
to that of growth hormone to the somatogenic receptor, i.e. essentially composed of residues belong- 
ing to this concave pocket. 
Prolactin (PRL), a 23-kDa pituitary-secreted hormone, is 
involved in more than 85 biological functions in vertebrates. 
These are mainly related to lactation, reproduction, growth, 
osmoregulation and immunomodulation (Nicoll and Bern, 
1972; Clarke and Bern, 1980). The hormonal signal is medi- 
ated by specific membrane receptors, or lactogenic receptors 
(Boutin et al., 1988; Edery et al., 1989), which are found in 
the numerous target tissues (Kelly et al., 1991). Several 
studies, aimed at determining which region of PRL interacts 
with the receptor, have been reported. Sequence comparisons 
(Nicoll et al., 1986; Luck et al., 1989), chemical modifica- 
tions (Doonen and Bewley, 1979; Andersen and Ebner, 
1979; Necessary et al., 1985; de la Llosa et al., 1985; for 
review, see Nicoll et al., 1986) or mutational studies (Luck 
et al., 1989, 1990, 1991 ; Goffin et al., 1992) characterized 
some structural features potentially involved in the biological 
properties of PRL but none of these data unequivocally local- 
ized the global PRL binding site. 
PRL belongs to a protein family also including growth 
hormone (GH) and placental lactogen. These hormones are 
evolutionarily related (Miller and Eberhardt, 1983) and share 
several structural, immunological and biological properties. 
To date, only the three-dimensionnal (3D) structures of por- 
cine GH (pGH) and human GH @GH) have been solved by 
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X-ray diffraction (Abdel-Meguid et al., 1987; de Vos et al., 
1992). These proteins fold in an antiparallel four-helix bun- 
dle with a characteristic up-up-down-down connectivity 
(Abdel-Meguid' et al., 1987). Given the sequence similarity 
within the PRL-GH family, this GH folding pattern is likely 
to be shared by all the members of the protein family. 
Through an extensive mutational study, Cunningham and his 
coworkers (Cunningham et al., 1989; Cunningham and 
Wells, 1989) have recently identified the binding site I of 
hGH to the somatogenic receptor (Leung et al., 1987) as 
formed of three segments, namely parts of helices 1 and 4 
and the second half of the long loop connecting helices 1 and 
2 (loop 1). Although discontinuous in the sequence, these 
three regions are contiguous on the folded protein and form 
a compact patch interacting with the receptor. The further X- 
ray analysis of the hGH-hGH-binding-protein complex (de 
Vos et al., 1992) allowed a better understanding of the hor- 
mone-receptor interaction and confirmed the existence of a 
second binding site as previously suggested by the muta- 
tional approach (Cunningham et al., 1991). 
Since, on one hand, the three segments constituting the 
binding site I of hGH are highly conserved within the PRL- 
GH family (Nicoll et al., 1986), and, on the other hand, the 
extracellular domains of the lactogenic and somatogenic re- 
ceptors share several segments of more than 70% identity 
(Kelly et al., 1991), one can assume the binding site of the 
PRL to be very similar, if not identical, to that described for 
hGH. This is in total agreement with our recent findings that 
some residues belonging to the loop 1 of hPRL are also 
essential for maintaining the biological properties of the hor- 
mone (Goffin et al., 1992). Nevertheless, involvement of 
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other regions, such as helices 1 and/or 4, has never been 
clearly demonstrated and the global shape of the PRL bind- 
ing site remains unknown. 
In this paper, we report structural and biological analyses 
of a hPRL mutant carrying nine extra residues at the C-termi- 
nus. From the structure/function studies of hGH, the C-termi- 
nal loop is at the edge of the hGH binding site I (Cunning- 
ham et al., 1989; Cunningham and Wells, 1989; de Vos et al., 
1992). Otherwise, it is maintained close to helix 4 through a 
disulfide bridge between Cys189 (C-terminal loop) and 
Cys182 (helix 4)(Abdel-Meguid et al., 1987; de Vos et al., 
1992). Hence, if the global shape of the PRL binding site is 
similar to that of hGH, one could expect the nine additional 
residues of this mutated hPRL to interfere with the hor- 
mone -receptor interaction and to alter the biological proper- 
ties of the hormone. 
MATERIALS AND METHODS 
Materials 
Restriction enzymes and ligase were purchased from 
Boehringer Mannheim (Germany), Amersham International 
(UK) and BRL (USA). Iodogen and bovine y-globulin were 
purchased from Sigma (USA) and carrier-free Nalz5I was ob- 
tained from Amersham International (UK). Taq polymerase 
was provided by Cetus (USA). Rabbit antiserum to hPRL 
was from UCB (Belgium) and goat anti-rabbit from Gamma 
SA (Belgium). Purification of hPRL was performed using 
a column (100 X 2.6 cm) of Sephadex G-100 (Pharmacia). 
Culture medium and sera were purchased from Gibco (USA). 
Mutagen e s i s 
The mutation of hPRL stop codon (TAA) to Gln (CAA) 
occurred unexpectedly during a routine polymerase chain re- 
action experiment performed to introduce a single mutation 
(Goffin et al., 1992) in the hPRL cDNA (Cooke et al., 1981). 
It was detected by DNA sequencing. The next stop codon on 
the same reading frame (TGA) is nine triplets further; this 
leads to the extension of the protein C-terminus by the nine 
following amino acids: Gln200, Ala201, His202, Ile203, 
His204, Phe205, Ile206, m 2 0 7 ,  Phe208. On account on its 
higher molecular mass (24 m a ) ,  this hPRL mutant is thus 
called 24-kDa hPRL. 
The NdeI-HindII1 mutated fragment of hPRL cDNA, 
containing the entirety of the 24-kDa hPRL coding sequence, 
was restricted at NdeI and HindIII sites and reinserted in 
the pT7L expression vector (Paris et al., 1990; Goffin et al., 
1992). 
Expression and purification of hPRL 
Expression and purification stages have been extensively 
described previously (Paris et al., 1990). Briefly, recombinant 
23-kDa and 24-kDa hPRL were overexpressed in Escher- 
ichia coli as insoluble aggregates, at a yield around 150 mg 
hPRL/l culture. These inclusion bodies were denaturated in 
8 M urea, 1 % 2-mercaptoethanol, 0.2 M sodium phosphate 
pH 7, and solubilized proteins were allowed to refold through 
a 72-h dialysis against 50 mM NKHCO, pH 8. Finally, rena- 
turated hPRL was loaded on a Sephadex G-100 column in 
order to separate monomers and multimers formed upon the 
renaturation step. Purified proteins were lyophilized for at 
least 24 h and conserved at 4°C. 
Quantification of hPRL 
Proteins were quantified by weighing the lyophilized 
powder on a precision balance (Electrobalance, Cahn 26) and 
by protein measurements following the Bradford method 
(1976). Disparity between weight and chemical measure- 
ments never exceeded 10%. 
Characterization of hPRL 
SDSPAGE 
Protein size and purity were assessed by SDSPAGE 
in reducing conditions (2-mercaptoethanol) according to 
Laemmli (1970). Electrophoresis was performed for 1 h at 
150 V and gels (15%) were stained with Coomassie blue. 
Western blotting 
After migration on SDSFAGE, proteins were transferred 
(90 min, 250 mA) to a nitrocellulose filter using a Transblot 
Cell apparatus (Bio-Rad). The filters were then treated with 
polyclonal rabbit anti-hPRL serum (1 h, 37°C) followed by 
a goat anti-rabbit preparation coupled with peroxidase (1 h, 
37OC). Final colour development occurred on addition of 
H,O, and horseradish peroxidase color development reagent 
(Bio-Rad). The reaction was stopped with 5% SDS. 
Circular dichroism 
Lyophilized proteins were resuspended in 50 mM 
NH,HCO, at a concentration of 200-500 pg/ml. Spectra 
were measured using a Jobin-Yvon dichrograph V linked to 
an Apple microcomputer for data recording and analysis. Ten 
measurements within the ranges 195-260nm and 240- 
330nm were made for each protein using a 0.1-cm path- 
length quartz cell. Helicity was calculated at 222 nm (Chen 
et al., 1972). 
Fourier-transform infrared spectroscopy 
Attenuated total reflectance spectra were obtained on a 
Perkin Elmer 1720X FTIR spectrophotometer equipped with 
a liquid nitrogen-cooled MCT detector, at a resolution of 
4 cm-I, by averaging 128 scans. Protein samples (500 pg/ml) 
were dialysed for 24 h against 1 mM Tris/HCl pH 8;  50 p1 
of each hPRL sample were layered on a germanium crystal 
and dried under nitrogen to form a hydrated film. The in- 
ternal reflection germanium crystal (50 X 20 X 2 mm, Har- 
rick) with a aperture angle of 45°C yields 25 internal reflec- 
tions. Every four scans, reference spectra of a clean germa- 
nium plate were automatically recorded and ratioed against 
the recently run sample spectra by an automatic sample 
shuttle accessory. The spectrophotometer was continuously 
purged with dry air. Helix and P-sheet content were estimated 
as described (Goormaghtigh et al., 1990). 
Nb2 cell culture and in vitro bioassay 
Human 23-kDa and 24-kDa PRL were assayed for lac- 
togen activity by measuring their ability to stimulate the 
growth of lactogen-dependent Nb2 lymphoma cells (Gout et 
al., 1980) following the procedure of Tanaka et al. (1980). 
Cells were cultured in Fischer's medium containing 10% 
horse serum and 10% fetal calf serum; 24 h before the bioas- 
says, cells were carefully centrifuged and resuspended in pre- 
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incubation medium containing only 1% fetal calf serum to 
reduce cell growth. Bioassays were performed in medium 
containing no fetal calf serum. 
Different amounts of hPRL samples, diluted in phos- 
phate-buffered saline, 0.1 % bovine serum albumin, were 
added to 2.5 ml cells (approximately lo5 cells/ml) plated in 
six-well Falcon plates. Each protein was assayed in duplicate 
at eight concentrations selected to induce detectable cell 
growth. Nb2 cells were counted after 3 days using a Coulter 
counter (Coulter Electronics Ltd, England). 
Iodination of hPRL 
Recombinant 23-kDa hPRL was iodinated by the iodogen 
method (Salacinski et al., 1981). 20 pg hPRL in 0.5 M so- 
dium phosphate pH 7.4 was transferred to a borosilicate glass 
coated with 10 pg iodogen. The reaction was initiated by 
addition of 1 mCi carrier-free Na1251. After 6 min at room 
temperature, the reaction was stopped by transferring the en- 
tire reaction mixture to a column (1 X 30 cm) of Sephadex 
G-100 equilibrated in 0.05 M sodium phosphate pH 7.4 con- 
taining 2% bovine serum albumin. Purified monomeric 
hPRL recovered after purification had a specific activity of 
40-50 pCi/pg. 
Binding experiments 
Studies on the binding of the 23-kDa and 24-kDa hPRL 
to the lactogenic receptor were performed on Nb2 cell ho- 
mogenates in order to avoid any internalization or degrada- 
tion of iodinated hPRL by intact cells. Nb2 cells were syn- 
chronized for 24 h in Fischer's medium in the absence of 
fetal calf serum to reduce occupancy of PRL receptors. Cells 
were pelleted, resuspended in the same medium at a concen- 
tration of 10' cells/ml and homogenized by freezing and 
thawing followed by a short sonication. Aliquots of homoge- 
nates were frozen at -70°C for subsequent use in binding 
assays. 
The assay conditions were described previously (Goffin 
et al., 1992). Homogenates, equivalent to 3 X lo6 cells, were 
transferred to Eppendorf tubes and incubated for 16 h at 
25°C with 40000-50000 cpm T-hPRL in the presence of 
increasing amounts of unlabelled 23-kDa or 24-kDa hPRL 
(the final reaction volume was 0.5 ml). The assay was termi- 
nated by addition of 0.5 ml ice-cold buffer (0.025 M Tris/ 
HCl, 0.01 M MgCl,, 0.2% bovine y-globulin, pH 7.5) fol- 
lowed by centrifugation (5 min, 11 000 X g ) .  The supernatant 
fraction was removed carefully and the pellets were counted 
in a gamma counter (Hybritech 002011B, Belgium). 
Binding measurements were performed in duplicate in 
three separate experiments. Specific binding was calculated 
as the difference between radioactivity bound in the absence 
and in the presence of 2 pg unlabelled 23-kDa WRL. Data 
are presented as the percentage of this specific binding. Com- 
petition curves were analyzed using the LIGAND PC pro- 
gram (Munson and Rodbard, 1980). 
Fig. 1. Polyacrylamide gel (15 %) electrophoresis (a) and Western 
blot analysis (b) of 23-kDa and 24-kDa WRL. Before electropho- 
resis (1 h, 150 V), the proteins were boiled for 5 min in sample 
buffer containing 2-mercaptoethanol. Lanes A, B and C represent 
24-M)a hPRL, 23-kDa hPRL and molecular mass markers (values 
in ma),  respectively. 
RESULTS 
Production and characterization 
of 23-kDa and 24-kDa hPRL 
Protein productions and purifications were carried out as 
previously described for the recombinant 23-kDa hPRL 
(Paris et al., 1990; Goffin et al., 1992). The expression level 
of 24-kDa hPRL was similar to that of the unmodified hPRL 
(around 100 mg insoluble inclusion bodiesh culture). After 
one denaturation and renaturation cycle, a gel filtration 
(Sephadex G-100) purification step allowed the recovery of 
around 15 mg 23-kDa or 24-kDa hPRLA culture. As shown 
in Fig. la,  the purified fractions are highly enriched in hPRL. 
Both proteins were tested with a polyclonal anti-hPRL anti- 
body preparation. Fig. l b  indicates that the 24-kDa hPRL 
reacts with the antibodies in a manner similar to the 23-kDa 
hPRL. 
Conformation of the proteins was assessed by circular 
dichroism (CD; Fig. 2) and Fourier-transform infrared spec- 
troscopy (FTIR). 
In the far-ultraviolet range (195 -260 nm), both proteins 
exhibit CD spectra characteristic of polypeptides containing 
residues primarily in a-helical conformation, with two min- 
ima at 208 nm and 222 nm and a maximum around 195 nm 
(Fig. 2a). The helicity calculated from the ellipticity at 
222nm according to Chen et al. (1972) is around 55% for 
23-kDa hPRL and 50% for 24-kDa hPRL. A similar differ- 
ence is obtained by FTIR, although the absolute percentage 
of helical structures is slightly under-estimated when com- 
pared to CD measurements (around 50% and 45% for 23- 
kDa and 24-kDa hPRL, respectively). FTIR also shows that 
the absorbance of the 24-kDa hPRL is significantly increased 
at 1631 cm-', indicating that 4% of its amino acids are in 
conformation (data not shown). No p structures were de- 
tected for the 23-kDa hPRL. Finally, the CD spectrum of 
both hPRL are also markedly different in the near-ultraviolet 
range (240-330 nm; Fig. 26). The positive CD bands in the 
240-290-nm range are higher for 24-kDa hPRL than for the 
23-kDa hPRL and curves cross the baseline towards negative 
bands at 248 nm and 241 nm, respectively. 
BioactivitY of 24-kDa h P m  
Bioactivity of the hPRL was estimated by the ability to 
stimulate proliferation of rat lymphoma Nb2 cells whose 
Secondary structure prediction 
The conformation of the elongated C-terminus tail of 
24-kDa hPRL has been predicted using three secondary 
structure prediction algorithms (Chou and Fasman, 1978 ; 
GOR method of Gamier et al., 1978; COMBINE method of 
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Fig. 2. Circular dichroic spectra in far ultraviolet (a) and near ultraviolet (b) of 23-kDa hPRL (-) and 24-kDa hPRL (---). Values 
are expressed as mean residue mass ellipticity (in deg. X cmz X dmol-'). Lyophilized proteins were resuspended in 50 mM ammonium 
bicarbonate, pH 8. Spectra were measured in a 0.1-cm path-length quartz cell. Helix content was calculated at the 222-nm minimum 
according to Chen et al. (1972). 
maximum response  (%I activity of 24-kDa hPRL was calculated as 3.3%, 1.6% and 
1% that of 23-kDa hPRL. 
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Fig.3. Nb2 cell proliferation in the presence of increasing 
amounts of 23-kDa or 24-kDa hPRL. In this experiment, half- 
maximal growth was achieved by addition of 170 pg 23-kDa hPlU/ 
ml and 5 ng 24-kDa hPlU/ml. 
growth is lactogen-dependent (Tanaka et al., 1980). Since 
recombinant 23-kDa hPRL behaves similarly to pituitary- 
purified hPRL (Goffin et al., 1992), it was used as reference 
in both bioactivity and binding assays (see further). Fig. 3 
represents Nb2 cell growth in the presence of increasing 
amounts of recombinant 23-kDa and 24-kDa hPRL. In all 
experiments, half-maximal cell growth occurred at 200 
2 4 0  pg of 23-kDa hPRL/ml culture. Bioactivity of 24-kDa 
hPRL was estimated as the ratio between the amount of 23- 
kDa hPRL compared to 24-kDa hPRL necessary to produce 
half-maximal cell growth. In W e  separate experiments, bio- 
Binding studies 
Binding affinities of the hPRL to the lactogenic receptor 
were measured on Nb2 cell homogenates. The affinity of the 
23-kDa and 24-kDa hPRL for the lactogenic receptor was 
estimated by their ability to compete for the binding of la- 
belled 23-kDa hPRL to Nb2 cell homogenates (Fig. 4). The 
concentration achieving 50% displacement of 23-kDa T- 
hPRL (I(&) was between 2-4ng/ml for 23-kDa hPRL, 
whereas it was 25-30-fold higher for 24-kDa hPRL. 
Secondary structure prediction 
As expected, structure prediction of 23-kDa and 24-kDa 
hPRL were indistinguishable in their common sequences 
(data not shown). The predicted fourth helix extremity was 
not shifted (Leul89). Whatever the algorithm used, the nine 
extra residues of 24-kDa hPRL (residues 200-208) were 
predicted to be essentially in p-strand or coil conformation 
(Fig. 5). 
DISCUSSION 
When the mutational approach is used to elucidate the 
role of some amino acids in the biological properties of a 
protein, it is of prime importance to verify that the residue 
substitution (or deletion) generates no modification of the 
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Fig. 4. Competitive binding curves of 23-kDa lUI-hPRL (tracer) 
and dabelled 23-kDa and 24-kDa hPRL (competitor). Binding 
of the tracer in the absence of competitor was taken as 100% bind- 
ing. Non-specific binding was determined by addition of 2 pg unla- 
belled 23-kDa hPK. Each point was performed in duplicate. In this 
experiment, concentration of competitor displacing 50% of the 
tracer (Z&,) was 4nglml for 23-kDa hPRL and 100nglml for 
24-kDa hPRL. 
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Fig.5. Secondary structure prediction of the C-terminal region 
of 24-kDa WRL performed using the COMBINE method of 
Biou et al. (1988). The putative extremities of WRL helix 4 are 
deduced from pGH and hGH X-ray structures. The nine extra resi- 
dues of 24-kDa hPRL are underlined and labelled 'elongation'. First 
line represents residue numbers, second line the C-terminal amino 
acid sequence of 24-kDa WRL, and third line the predicted confor- 
mation (H = a helix, B = /? strand, C = coil). 
global protein structure that could be more responsible for 
an alteration in the biological behavior than the mutation per 
se. As an example, Luck et al. (1990) observed a dramatic 
decrease of the Nb2 mitogenic effect of bovine PRL after the 
single deletion of Tyr28 whereas any residue substitution at 
this position was much less effective. Since Tyr28 belongs 
to an a-helix, its removal modifies the register of the whole 
helical segment, disturbs the global protein folding and, 
hence, is very likely to alter the functional properties of 
bPF& Otherwise, the residue itself should not be a major 
binding determinant since it can be substituted by any other 
amino-acid without significant loss of bioactivity. 
The global shape of 24-kDa hPRL is not altered since its 
elution volume on a molecular sieve during the purification 
procedure was indistinguishable from that of 23-kDa hPRL. 
Since the P W G H  are all a proteins, far-ultraviolet circular 
dichroism (CD) is a good tool for estimating their content of 
secondary structures (Bewley and Li, 1972; Goffin et al., 
1992). The far-ultraviolet CD spectrum of 24-kDa hPRL is 
similar to that of the native 23-kDa hPRL, with the two min- 
ima at 208 nm and 222 nm, characteristic of polypeptides 
with high helical content. The amount of a-helical structures 
was estimated to be 55% for 23-kDa hPRL and 50% for 
24-kDa hPRL. A similar difference between both proteins 
(around 5%)  was observed by FTIR. The slightly lower heli- 
cal content calculated for the 24-kDa hPRL could be partially 
related to the addition of nine residues which decreases the 
overall average of helical content. Although a small loss of 
a-helical structures in the 24-kDa hPRL cannot be ruled out 
from these experiments, it appears nevertheless that the elon- 
gation of the C-terminal tail by addition of nine residues has 
no effect, or at least no detectable effect, on the global fold- 
ing of the protein. 
We observed more important differences between the CD 
spectra of 23-kDa and 24-kDa hPlU in the 240-330-nm 
range. These can be related to the presence, in the elongated 
C-terminus, of aromatic residues (Phe205, Tyr207 and 
Phe208), increasing the CD signal in this wavelength range. 
Similar changes of the near-ultraviolet CD spectrum have 
also been previously reported after deletion or mutation of 
Trp in hGH (Nishikawa et al., 1989). 
Without X-ray or NMR data, it is obviously impossible 
to determine the actual 3D structure of the nine extra residues 
extending the C-terminus of 24-kDa hPRL. The three sec- 
ondary prediction algorithms we used (Chou and Fasman, 
1978; Gamier et al., 1978; Biou et al., 1988) all suggest that 
the elongated C-terminus of 24-kDa hPRL presents j3-strand 
and coil conformations. This is relevant to the data obtained 
by FTIR from which nearly 4% of the amino acids of the 
24-kDa hPRL are in P conformation. Although very weak, 
such an increase of the &sheet content can be considered as 
significant since obtained from comparison of the original 
spectra, before Fourier transform and curve fitting that can 
introduce artefacts. The increase of p structures in the mutant 
is comcomitant to a similar decrease of the a-helical content 
( -5%,  see above). One can thus assume that some residues 
initially involved in the fourth helix of 23-kDa hPRL adopt 
a p structure in the 24-kDa hPRL to form a small P-sheet 
with some residues of the elongated C-terminus (Ile203- 
Ile206 from Biou prediction). Two p-strands of four or five 
residues could thus account for the 4% of j? structures calcu- 
lated from the analysis of FTIR spectra. Such local modifica- 
tion of the structure could also be responsible for the small 
shift in wavelength detected in the 200-240-nm range of the 
CD spectrum. 
A possible location for this elongated tail can be pro- 
posed from the analysis of the general folding of the PRL/ 
GH proteins (Abdel-Meguid et al., 1987; de Vos et al., 1992), 
illustrated in Fig. 6. From this model, the C-terminus folds 
in a coil segment of six (PRL) to eight (GH) residues, main- 
tained near helix 4 by a disulfide bridge (Cysl91 -Cys199 
in hPRL, Cys182-Cys189 in hGH). Otherwise, the N-termi- 
nal part of helix 1, the C-terminal part of helix 4 and the 
second half of loop 1 delimit a pocket with a concave shape 
(de Vos et al., 1992). Hence, we propose that the nine extra 
residues of 24-kDa hPRL fold very near, or even within, this 
concave cavity. Such a hypothesis is in agreement with the 
overall length of nine residues as well as with their highly 
hydrophobic character (Ile203, Phe205, Ile206, Tyr207, 
Phe208), that makes them candidates for being buried rather 
than exposed at the surface of the protein. 
Taken together, experimental and theoretical data suggest 
that the entire elongated tail of 24-kDa hPRL folds in the 
environment of the 'helix-1 - helix-4-loop-1' concave cav- 
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Fig. 6. Schematic view of the P W G H  three-dimensional folding 
(Abdel-Meguid et al., 1987). Helices are represented by cylinders 
and labelled from 1 to 4. Disulfide bridges are represented by S-S. 
The circle localizes the binding site of hGH to its somatogenic re- 
ceptor (Cunningham et al., 1989). The 58-74 loop region, involved 
in hPRL binding (Goffin et al., 1992), is striated. The position of 
Lys 69, a major binding determinant of WRL, is roughly indicated. 
A possible location for the nine additional residues at the C-terminus 
of 24-kDa hPRL is shown in black. 
ity, with a few of the nine extra residues being involved in a 
/3-sheet with some residues initially belonging to the fourth 
helix of the wild-type 23-kDa hPRL. 
Functional properties of the 24-kDa hPRL were esti- 
mated by measuring its ability, first, to bind to the lactogenic 
receptor of Nb2 cells and, second, to induce Nb2 cell divi- 
sion (Tanaka et al., 1980; Gout et al., 1980). Nb2 cells are a 
rat lymphoma cell line that is lactogen-dependent for growth; 
thus, it provides a reliable bioassay widely used for evaluat- 
ing biological potency of lactogenic hormones (Luck et al., 
1989,1990,1991 ; Davis and Linzer, 1989; Paris et al., 1990; 
Goffin et al., 1992). It has been previously reported that re- 
ceptor binding of mutated lactogenic proteins is not necessar- 
ily a sufficient event for promoting Nb2 cell division (Davis 
and Linzer, 1989). In the case of the 24-kDa hPRL, both its 
binding affinity and mitogenicity are reduced by 50-100- 
fold compared to the 23-kDa hPRL. This leads to the conclu- 
sion that the lower mitogenic effect of the mutant results 
essentially from a lower binding affinity rather than from any 
alteration of the signal transduction process. 
Since the global fold of the hormone is likely to remain 
virtually unchanged after the elongation of the C-terminus 
(see above), one can assume that these modifications of the 
biological behavior are directly correlated with the structural 
modifications occurring in the environment of the nine addi- 
tional residues. In other words, the mutation is likely to affect 
mainly the binding site of hPRL to its receptor. 
In hGH, most of the binding determinants involved in 
the binding site I belong to the concave pocket delimited by 
segments of helix 1, helix 4 and loop 1 (Cunningham and 
Wells, 1989; de Vos et al., 1992). The 3D structure of the 
hGH- hGH-binding-protein complex also shows that binding 
site I is mostly buried upon the hormone -receptor interac- 
tion (de Vos et al., 1992). We have recently proposed the 
binding site of PRL to be similar to that described for hGH, 
and we have partly confirmed this hypothesis by identifying 
some residues belonging to loop 1 of hPRL as binding deter- 
minants (GofFn et al., 1992). In the present work, we have 
hypothezised that the nine extra residues of 24-kDa hPRL 
fold within (or very near) the ‘helix-1 -helix-4-loop-l’ cav- 
ity. This proposal, correlated with the lower biological po- 
tency of the mutant, suggests this concave pocket to be in- 
volved in the binding site of hPRL. This is therefore relevant 
to what has been demonstrated for hGH and strengthens our 
earlier hypothesis. 
There may be two different ways by which the nine extra 
residues alter the biological properties of the 24-kDa hPRL. 
On one hand, by its steric hindrance, the elongated tail proba- 
bly prevents some binding determinants belonging to the 
concave pocket from interacting more tightly with the recep- 
tor. At first sight, the residues whose binding is affected can 
be located in either of the three segments constituting this 
binding cavity (loop 1, helices 1 and 4). On the other hand, 
the probable conformational modifications occurring in the 
fourth helix (local replacement of a structures by j? struc- 
tures), as a direct consequence of the potein elongation, could 
prevent some residues specifically belonging to this helix 
from interacting with the receptor. This latter proposal does 
not question our hypothesis concerning the biological impor- 
tance of the concave pocket since the fourth helix belongs to 
this binding cavity. It may in fact underline the functional 
involvement of that particular helical segment. 
In the 58-74 region (loop l) ,  we have recently identified 
Cys58, Pro66 and Lys69 as three major binding determinants 
(Goffin et al., 1992). The role of Cys58 is essentially struc- 
tural, in that the disulfide bridge it forms with Cys174 main- 
tains the whole loop 1 in an appropriate conformation for a 
tight binding to the receptor. From the GH fold (Abdel-Me- 
guid et al., 1987; de Vos et al., 1992), Pro66 is in the interior 
of the binding cavity; since the pyrollidine ring of Pro resi- 
dues places strong conformational constraints on the back- 
bone, the role of that residue could also be essentially struc- 
tural. These observations suggest that Cys58 and Pro66 are 
not directly involved in a contact with the receptor through 
their side chains, but rather participate in maintaining the 
global shape of the binding site of hPRL. Hence, the steric 
hindrance of the elongated tail of 24-kDa hPRL has probably 
no, or only very low, effect on the functional role of these 
two residues. The third binding residue of this segment, 
Lys69, is located at the edge of the concave pocket (Fig. 6). 
It is fully exposed to the solvent and is in a conformation 
which should be favorable for direct interaction with a dock- 
ing receptor molecule. From the location we proposed for the 
elongated tail of 24-kDa hPRL (Fig. 6), the nine additional 
residues should not interfere with the Lys69, even if some 
structural disturbance cannot be totally excluded. In conclu- 
sion, we think that the reduced bioactivity of 24-kDa hPRL 
cannot only result from a steric effect of the elongated tail 
on loop 1 residues, but is rather a consequence of a more 
global alteration of the whole hPRL binding site. 
Thus, from these observations, we propose that some re- 
gions of helices 1 and/or 4, as structural parts of the concave 
pocket, are also involved in the binding site of PRL. Our 
results are in agreement with those of Luck et al. (1991) who 
recently reported that Arg177, localized in the middle of he- 
lix 4, is essential for the mitogenic effect of bPRL on Nb2 
cells. Similarly, involvement of helix 4 in the PRL binding 
site could also account for the weak lactogenic and mitogenic 
properties of 16-kDa prolactin (Clapp et al., 1988), a natural 
PRL mutant which lacks the C-terminal third of intact PRL, 
including the whole of helix 4. 
In conclusion, the results we have obtained with 24-kDa 
hPRL appear particularly complementary to our earlier find- 
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